PA
BBIO icon

Parallel Advisors’s BridgeBio Pharma BBIO Stock Holding History

Parallel Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.8K Sell
843
-51
-6% -$3.57K ﹤0.01% 1987
2026
Q1 		$66.4K Buy
894
+757
+553% +$54.9K ﹤0.01% 1827
2025
Q4 		$10.5K Buy
137
+6
+5% +$394 ﹤0.01% 2590
2025
Q3 		$6.8K Hold
131
– – ﹤0.01% 2658
2025
Q2 		$5.66K Buy
131
+10
+8% +$364 ﹤0.01% 2696
2025
Q1 		$4.18K Sell
121
-3
-2% -$101 ﹤0.01% 2738
2024
Q4 		$3.4K Sell
124
-317
-72% -$8.19K ﹤0.01% 2787
2024
Q3 		$11.2K Buy
441
+405
+1,125% +$10.6K ﹤0.01% 2354
2024
Q2 		$912 Buy
+36
New +$984 ﹤0.01% 2984
2023
Q4 		– Sell
-28
Closed -$738 – 3335
2023
Q3 		$738 Hold
28
– – ﹤0.01% 3029
2023
Q2 		$482 Hold
28
– – ﹤0.01% 3108
2023
Q1 		$464 Hold
28
– – ﹤0.01% 3139
2022
Q4 		$213 Buy
+28
New +$268 ﹤0.01% 3178
2022
Q3 		– Sell
-34
Closed – – 3142
2022
Q2 		$0 Buy
+34
New +$284 ﹤0.01% 2998
2022
Q1 		– Sell
-121
Closed -$2K – 2971
2021
Q4 		$2K Sell
121
-367
-75% -$15.5K ﹤0.01% 2660
2021
Q3 		$23K Hold
488
– – ﹤0.01% 1652
2021
Q2 		$30K Sell
488
-545
-53% -$31.1K ﹤0.01% 1471
2021
Q1 		$64K Buy
+1,033
New +$67.6K ﹤0.01% 1065

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Parallel Advisors's BBIO Position: Q2 2026 in Review

Parallel Advisors reduced its BridgeBio Pharma (BBIO) stake by 5.7% in Q2 2026, selling an estimated $3.57K and leaving 843 shares worth $62.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1987.

Parallel Advisors first reported a position in BBIO in Q1 2021 and has held it in 18 quarters since. The position peaked at $66.4K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Parallel Advisors held 843 shares of BridgeBio Pharma worth $62.8K as of Q2 2026.
  • Parallel Advisors sold 51 BridgeBio Pharma shares in Q2 2026, an estimated $3.57K.
  • BridgeBio Pharma made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1987 holding.
  • Parallel Advisors first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 18 quarters since.
  • Parallel Advisors's BridgeBio Pharma position peaked at $66.4K in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.